In the United States, ~22,000 women are diagnosed with ovarian cancer every year, and unfortunately, ~14,000 die from this disease. Platinum resistant patients have a lower 5 year progression-free survival rate of 30% which correlates with the development of recurrent disease.

We will evaluate combination drug regimens in women with low response rates to platinum-based chemotherapy treatment. Consequently, we aim to improve the quality of life for advanced stage patients by identifying a novel treatment strategy.

It is crucial for us to understand the mechanism of action for existing drugs and develop a different therapeutic approach for patients with poor prognosis.